1.
Leuk Res Rep
; 19: 100360, 2023.
Article
in English
| MEDLINE
| ID: mdl-36590864
ABSTRACT
Despite widespread use of Pegylated forms of Inteferon in the management of Myeloproliferative Neoplasms (MPN), most clinicians have experience predominantly with peginterferon alfa-2a (Pegasys). Third generation pegylated IFNα, ropeginterferon alfa-2b (ropegIFN; Besremi), was recommended by the European Medicine Authority (EMA) for treatment of Polycythaemia Vera (PV) following a Phase III trial (PROUD-PV / CONTINUATION-PV). FDA approval for PV, regardless of treatment history, was subsequently granted in November 2021. We hereby demonstrate the safety and tolerability of ropegIFN in a series of MPN patients at variable doses. It corroborates reports of efficacy of ropegIFN in patients with PV and use in pregnancy.
2.
Br J Haematol
; 190(4): e248-e250, 2020 08.
Article
in English
| MEDLINE
| ID: mdl-32428243
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , COVID-19 Drug Treatment , COVID-19 , Leukemia, Promyelocytic, Acute , SARS-CoV-2 , Adult , Arsenic Trioxide/administration & dosage , COVID-19/diagnosis , Humans , Leukemia, Promyelocytic, Acute/diagnosis , Leukemia, Promyelocytic, Acute/drug therapy , Male , Tretinoin/administration & dosage
3.
Hematology
; 20(3): 182-3, 2015 Apr.
Article
in English
| MEDLINE
| ID: mdl-25801784